368 related articles for article (PubMed ID: 33047263)
1. Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.
Palmowski A; Buttgereit F
Curr Rheumatol Rep; 2020 Oct; 22(12):85. PubMed ID: 33047263
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
Hellmich B; Águeda AF; Monti S; Luqmani R
Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
[TBL] [Abstract][Full Text] [Related]
3. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Hellmich B; Agueda A; Monti S; Buttgereit F; de Boysson H; Brouwer E; Cassie R; Cid MC; Dasgupta B; Dejaco C; Hatemi G; Hollinger N; Mahr A; Mollan SP; Mukhtyar C; Ponte C; Salvarani C; Sivakumar R; Tian X; Tomasson G; Turesson C; Schmidt W; Villiger PM; Watts R; Young C; Luqmani RA
Ann Rheum Dis; 2020 Jan; 79(1):19-30. PubMed ID: 31270110
[TBL] [Abstract][Full Text] [Related]
4. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411
[TBL] [Abstract][Full Text] [Related]
5. Biologic treatment of large-vessel vasculitides.
Schäfer VS; Zwerina J
Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
[TBL] [Abstract][Full Text] [Related]
6. Comparing treatment options for large vessel vasculitis.
Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
[TBL] [Abstract][Full Text] [Related]
7. Biotherapies in large vessel vasculitis.
Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
[TBL] [Abstract][Full Text] [Related]
8. [Large-vessel vasculitis-giant cell and Takayasu arteritis].
Villiger PM
Internist (Berl); 2019 Oct; 60(10):1059-1073. PubMed ID: 31471629
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab: a novel therapy for patients with large-vessel vasculitis.
Salvarani C; Magnani L; Catanoso M; Pipitone N; Versari A; Dardani L; Pulsatelli L; Meliconi R; Boiardi L
Rheumatology (Oxford); 2012 Jan; 51(1):151-6. PubMed ID: 22075063
[TBL] [Abstract][Full Text] [Related]
10. Management of large-vessel vasculitis.
Salvarani C; Hatemi G
Curr Opin Rheumatol; 2019 Jan; 31(1):25-31. PubMed ID: 30461542
[TBL] [Abstract][Full Text] [Related]
11. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab: a new therapy for large vessel vasculitis.
Al-Homood IA
Clin Exp Med; 2014 Nov; 14(4):355-60. PubMed ID: 23949338
[TBL] [Abstract][Full Text] [Related]
13. Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides.
Mendel A; Ennis D; Carette S; Pagnoux C
Clin Exp Rheumatol; 2021; 39 Suppl 129(2):119-124. PubMed ID: 33338004
[TBL] [Abstract][Full Text] [Related]
14. New treatment strategies in large-vessel vasculitis.
Unizony S; Stone JH; Stone JR
Curr Opin Rheumatol; 2013 Jan; 25(1):3-9. PubMed ID: 23114585
[TBL] [Abstract][Full Text] [Related]
15. Biotherapies in large vessel vasculitis.
Pazzola G; Muratore F; Pipitone N; Salvarani C
Rev Med Interne; 2016 Apr; 37(4):274-8. PubMed ID: 26383765
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Narváez J; Estrada P; LLop D; Vidal-Montal P; Brugarolas E; Maymó-Paituvi P; Palacios-Olid J; Nolla JM
Semin Arthritis Rheum; 2023 Apr; 59():152166. PubMed ID: 36645992
[TBL] [Abstract][Full Text] [Related]
17. Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
Muratore F; Pipitone N; Salvarani C
Expert Rev Clin Immunol; 2017 Apr; 13(4):345-360. PubMed ID: 28116918
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis.
Dumont A; Parienti JJ; Delmas C; Boutemy J; Maigné G; Martin Silva N; Sultan A; Planchard G; Aouba A; de Boysson H
J Rheumatol; 2020 Jan; 47(1):108-116. PubMed ID: 30877210
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of JAK Inhibitors for Large Vessel Vasculitis.
Watanabe R; Hashimoto M
Front Immunol; 2022; 13():881705. PubMed ID: 35432355
[TBL] [Abstract][Full Text] [Related]
20. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
